Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 16, 2016 - Issue 2
Submit an article Journal homepage
3,374
Views
27
CrossRef citations to date
0
Altmetric
Reviews

Alternative pharmacological strategies for adult ADHD treatment: a systematic review

Massimiliano BuoliDepartment of Psychiatry, Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy;Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The NetherlandsCorrespondence[email protected]
,
Marta SeratiDepartment of Psychiatry, Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy
&
Wiepke CahnDepartment of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
Pages 131-144 | Received 22 Oct 2015, Accepted 21 Dec 2015, Published online: 14 Jan 2016

References

  • Papers of special note have been highlighted as:
  • • of interest
  • •• of considerable interest
  • Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry. 2007;190:402–409.
  • Mao AR, Findling RL. Comorbidities in adult attention-deficit/hyperactivity disorder: a practical guide to diagnosis in primary care. Postgrad Med. 2014;126:42–51.
  • Kooij SJ, Bejerot S, Blackwell A, et al. European consensus statement on diagnosis and treatment of adult ADHD: the European Network Adult ADHD. BMC Psychiatry. 2010;10:67.
  • Levy F. The dopamine theory of attention deficit hyperactivity disorder (ADHD). Aust N Z J Psychiatry. 1991;25:277–283.
  • Cornish KM, Manly T, Savage R, et al. Association of the dopamine transporter (DAT1) 10/10-repeat genotype with ADHD symptoms and response inhibition in a general population sample. Mol Psychiatry. 2005;10:686–698.
  • Shaw P, Malek M, Watson B, et al. Trajectories of cerebral cortical development in childhood and adolescence and adult attention-deficit/hyperactivity disorder. Biol Psychiatry. 2013;74:599–606.
  • Sharma A, Couture J. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann Pharmacother. 2014;48:209–225.
  • Arnsten AF. The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder. Expert Rev Neurother. 2010;10:1595–1605.
  • Moffitt TE, Houts R, Asherson P, et al. Is adult ADHD a childhood-onset neurodevelopmental disorder? Evidence from a four-decade longitudinal cohort study. Am J Psychiatry [Internet]. 2015.

• Etiology of adult ADHD.

  • Zetterqvist J, Asherson P, Halldner L, et al. Stimulant and non-stimulant attention deficit/hyperactivity disorder drug use: total population study of trends and discontinuation patterns 2006–2009. Acta Psychiatr Scand. 2013;128:70–77.
  • Castells X, Ramos-Quiroga JA, Rigau D, et al. Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis. CNS Drugs. 2011;25:157–169.

•• Meta-analysis of efficacy of methylphenidate.

  • Asherson P, Bushe C, Saylor K, et al. Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: an integrated analysis of the complete database of multicenter placebo-controlled trials. J Psychopharmacol. 2014;28:837–846.

•• Meta-analysis of efficacy of atomoxetine.

  • Ginsberg Y, Beusterien KM, Amos K, et al. The unmet needs of all adults with ADHD are not the same: a focus on Europe. Expert Rev Neurother. 2014;14:799–812.

• Limits of the current ADHD pharmacotherapy.

  • Castells X, Cunill R, Capellà D. Treatment discontinuation with methylphenidate in adults with attention deficit hyperactivity disorder: a meta-analysis of randomized clinical trials. Eur J Clin Pharmacol. 2013;69:347–356.
  • Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2001;58:775–782.
  • Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr. 2006;11:625–639.
  • Spencer TJ, Adler LA, Weisler RH, et al. Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study. J Clin Psychiatry. 2008;69:1437–1448.
  • Levin FR, Mariani JJ, Specker S, et al. Extended-release mixed amphetamine salts vs placebo for comorbid adult attention-deficit/hyperactivity disorder and cocaine use disorder: a randomized clinical trial. JAMA Psychiatry. 2015;72:593–602.
  • Wigal T, Brams M, Gasior M, et al. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behav Brain Funct. 2010;6:34.
  • Adler LA, Dirks B, Deas PF, et al. Lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2013;74:694–702.
  • Weisler R, Ginsberg L, Dirks B, et al. Treatment with lisdexamfetamine dimesylate improves self- and informant-rated executive function behaviors and clinician- and informant-rated adhd symptoms in adults: data from a randomized, double-blind, placebo-controlled study. J Atten Disord. 2014. Epub ahead of print.
  • Manor I, Newcorn JH, Faraone SV, et al. Efficacy of metadoxine extended release in patients with predominantly inattentive subtype attention-deficit/hyperactivity disorder. Postgrad Med. 2013;125:181–190.
  • Manor I, Rubin J, Daniely Y, et al. Attention benefits after a single dose of metadoxine extended release in adults with predominantly inattentive ADHD. Postgrad Med. 2014;126:7–16.
  • Surman CB, Hammerness PG, Petty C, et al. A pilot open label prospective study of memantine monotherapy in adults with ADHD. World J Biol Psychiatry. 2013;14:291–298.
  • Biederman J, Fried R, Tarko L, et al. Memantine in the treatment of executive function deficits in adults with adhd: a pilot-randomized double-blind controlled clinical trial. J Atten Disord. 2014. Epub ahead of print.
  • Potter AS, Dunbar G, Mazzulla E, et al. AZD3480, a novel nicotinic receptor agonist, for the treatment of attention-deficit/hyperactivity disorder in adults. Biol Psychiatry. 2014;75:207–214.
  • Herring WJ, Wilens TE, Adler LA, et al. Randomized controlled study of the histamine H3 inverse agonist MK-0249 in adult attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2012;73:e891–e898.
  • Taylor FB, Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol. 2000;10:311–320.
  • Turner DC, Clark L, Dowson J, et al. Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biol Psychiatry. 2004;55:1031–1040.
  • Arnold VK, Feifel D, Earl CQ, et al. A 9-week, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy and safety of modafinil as treatment for adults with ADHD. J Atten Disord. 2014;18:133–144.
  • Adler LA, Gorny SW. Pilot study of droxidopa with carbidopa in adults with ADHD. J Atten Disord. 2015. Epub ahead of print.
  • Wilens TE, Biederman J, Mick E, et al. A systematic assessment of tricyclic antidepressants in the treatment of adult attention-deficit hyperactivity disorder. J Nerv Ment Dis. 1995;183:48–50.
  • Wilens TE, Biederman J, Prince J, et al. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry. 1996;153:1147–1153.
  • Weiss M, Hechtman L; Adult ADHD Research Group. A randomized double-blind trial of paroxetine and/or dextroamphetamine and problem-focused therapy for attention-deficit/hyperactivity disorder in adults. J Clin Psychiatry. 2006;67:611–619.
  • Wender PH, Reimherr FW. Bupropion treatment of attention-deficit hyperactivity disorder in adults. Am J Psychiatry. 1990;147:1018–1020.
  • Kuperman S, Perry PJ, Gaffney GR, et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Ann Clin Psychiatry. 2001;13:129–134.
  • Wilens TE, Spencer TJ, Biederman J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry. 2001;158:282–288.
  • Levin FR, Evans SM, McDowell DM, et al. Bupropion treatment for cocaine abuse and adult attention-deficit/hyperactivity disorder. J Addict Dis. 2002;21:1–16.
  • Reimherr FW, Hedges DW, Strong RE, et al. Bupropion SR in adults with ADHD: a short-term, placebo-controlled trial. Neuropsychiatr Dis Treat. 2005;1:245–251.
  • Wilens TE, Haight BR, Horrigan JP, et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry. 2005;57:793–801.
  • Hamedi M, Mohammdi M, Ghaleiha A, et al. Bupropion in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind study. Acta Med Iran. 2014;52:675–680.
  • Riahi F, Tehrani-Doost M, Shahrivar Z, et al. Efficacy of reboxetine in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial. Hum Psychopharmacol. 2010;25:570–576.
  • Hashemian F, Mohammadian S, Riahi F, et al. A comparison of the effects of reboxetine and placebo on reaction time in adults with attention deficit-hyperactivity disorder (ADHD). Daru. 2011;19:231–235.
  • Amiri S, Farhang S, Ghoreishizadeh MA, et al. Double-blind controlled trial of venlafaxine for treatment of adults with attention deficit/hyperactivity disorder. Hum Psychopharmacol. 2012;27:76–81.
  • Bilodeau M, Simon T, Beauchamp MH, et al. Duloxetine in adults with ADHD: a randomized, placebo-controlled pilot study. J Atten Disord. 2014;18:169–175.
  • Dorrego MF, Canevaro L, Kuzis G, et al. A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. J Neuropsychiatry Clin Neurosci. 2002;14:289–295.
  • Sutherland SM, Adler LA, Chen C, et al. An 8-week, randomized controlled trial of atomoxetine, atomoxetine plus buspirone, or placebo in adults with ADHD. J Clin Psychiatry. 2012;73:445–450.
  • Biederman J, Mick E, Faraone S, et al. A double-blind comparison of galantamine hydrogen bromide and placebo in adults with attention-deficit/hyperactivity disorder: a pilot study. J Clin Psychopharmacol. 2006;26:163–166.
  • Koblan KS, Hopkins SC, Sarma K, et al. Dasotraline for the treatment of attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled, proof-of-concept trial in adults. Neuropsychopharmacology 2015;40:2745–2752.
  • Chiellini G, Nesi G, Digiacomo M, et al. Design, synthesis and evaluation of thyronamine analogues as novel potent mouse trace amine associated receptor 1 (mTAAR1) agonists. J Med Chem. 2015;58:5096–5107.
  • Weisler RH. Safety, efficacy and extended duration of action of mixed amphetamine salts extended-release capsules for the treatment of ADHD. Expert Opin Pharmacother. 2005;6:1003–1018.
  • Coghill DR, Caballero B, Sorooshian S, et al. A systematic review of the safety of lisdexamfetamine dimesylate. CNS Drugs. 2014;28:497–511.
  • Adler LA, Alperin S, Leon T, et al. Clinical effects of lisdexamfetamine and mixed amphetamine salts immediate release in adult ADHD: results of a crossover design clinical trial. Postgrad Med. 2014;126:17–24.
  • Oades RD. Dopamine-serotonin interactions in attention-deficit hyperactivity disorder (ADHD). Prog Brain Res. 2008;172:543–565.
  • Brea J, Castro-Palomino J, Yeste S, et al. Emerging opportunities and concerns for drug discovery at serotonin 5-HT2B receptors. Curr Top Med Chem. 2010;10:493–503.
  • Pomerleau OF, Downey KK, Stelson FW, et al. Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. J Subst Abuse. 1995;7:373–378.
  • Potter AS, Newhouse PA. Acute nicotine improves cognitive deficits in young adults with attention-deficit/hyperactivity disorder. Pharmacol Biochem Behav. 2008;88:407–417.
  • Jucaite A, Öhd J, Potter AS, et al. A randomized, double-blind, placebo-controlled crossover study of α4β 2* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl). 2014;231:1251–1265.
  • Martin CA, Nuzzo PA, Ranseen JD, et al. Lobeline effects on cognitive performance in adult ADHD. J Atten Disord. 2013. Epub ahead of print.
  • Hosking JG, Lam FC, Winstanley CA. Nicotine increases impulsivity and decreases willingness to exert cognitive effort despite improving attention in “slacker” rats: insights into cholinergic regulation of cost/benefit decision making. PLoS One. 2014;9:e111580.
  • Potter AS, Ryan KK, Newhouse PA. Effects of acute ultra-low dose mecamylamine on cognition in adult attention-deficit/hyperactivity disorder (ADHD). Hum Psychopharmacol. 2009;24:309–317.
  • Vohora D, Bhowmik M. Histamine H3 receptor antagonists/inverse agonists on cognitive and motor processes: relevance to Alzheimer’s disease, ADHD, schizophrenia, and drug abuse. Front Syst Neurosci. 2012;6:72.
  • Wisor J. Modafinil as a catecholaminergic agent: empirical evidence and unanswered questions. Front Neurol. 2013;4:139.
  • Kaufmann H, Norcliffe-Kaufmann L, Palma J-A. Droxidopa in neurogenic orthostatic hypotension. Expert Rev Cardiovasc Ther. 2015;13:875–891.
  • Higashino K, Ago Y, Umehara M, et al. Effects of acute and chronic administration of venlafaxine and desipramine on extracellular monoamine levels in the mouse prefrontal cortex and striatum. Eur J Pharmacol. 2014;729:86–93.
  • Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007;151:737–748.
  • Banerjee E, Nandagopal K. Does serotonin deficit mediate susceptibility to ADHD? Neurochem Int. 2015;82:52–68.
  • Chevassus H, Farret A, Gagnol J-P, et al. Psychological and physiological effects of bupropion compared to methylphenidate after prolonged administration in healthy volunteers (NCT00285155). Eur J Clin Pharmacol. 2013;69:779–787.
  • Giers G, Salama A, Mueller-Eckhardt C. Follow-up study on 24 patients with nomifensine-induced immune haemolytic anaemia. Transfus Med. 1991;1:115–119.
  • Shekim WO, Masterson A, Cantwell DP, et al. Nomifensine maleate in adult attention deficit disorder. J Nerv Ment Dis. 1989;177:296–299.
  • Chamberlain SR, Müller U, Blackwell AD, et al. Noradrenergic modulation of working memory and emotional memory in humans. Psychopharmacology (Berl). 2006;188:397–407.
  • Takano A, Halldin C, Farde L. SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: a PET study. Psychopharmacology (Berl). 2013;226:147–153.
  • Hedges D, Reimherr FW, Rogers A, et al. An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder. Psychopharmacol Bull. 1995;31:779–783.
  • Adler LA, Resnick S, Kunz M, et al. Open-label trial of venlafaxine in adults with attention deficit disorder. Psychopharmacol Bull. 1995;31:785–788.
  • Findling RL, Schwartz MA, Flannery DJ, et al. Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial. J Clin Psychiatry. 1996;57:184–189.
  • Park P, Caballero J, Omidian H. Use of serotonin norepinephrine reuptake inhibitors in the treatment of attention-deficit hyperactivity disorder in pediatrics. Ann Pharmacother. 2014;48:86–92.
  • Arnsten AF, Pliszka SR. Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders. Pharmacol Biochem Behav. 2011;99:211–216.
  • Taylor FB, Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2001;21:223–228.
  • Torres I, Gómez N, Colom F, et al. Bipolar disorder with comorbid attention-deficit and hyperactivity disorder. Main clinical features and clues for an accurate diagnosis. Acta Psychiatr Scand. 2015;132:389–399.
  • Altamura AC. Therapeutic attempts with lithium in young drug addicts. Acta Psychiatr Scand. 1975;52:312–319.
  • Ghanizadeh A. Systematic review of clinical trials of aripiprazole for treating attention deficit hyperactivity disorder. Neurosciences (Riyadh). 2013;18:323–329.
  • Kikukawa S. Effectiveness of aripiprazole in treatment of adults with attention deficit disorder and restless legs syndrome. Int J Neuropsychopharmacol. 2008;11:439–440.
  • De Boer SF, Koolhaas JM. 5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis. Eur J Pharmacol. 2005;526:125–139.
  • Bracco L, Bessi V, Padiglioni S, et al. Do cholinesterase inhibitors act primarily on attention deficit? A naturalistic study in Alzheimer’s disease patients. J Alzheimer Dis. 2014;40:737–742.
  • Sunderland T, Cohen RM, Molchan S, et al. High-dose selegiline in treatment-resistant older depressive patients. Arch Gen Psychiatry. 1994;51:607–615.
  • Ernst M, Liebenauer LL, Jons PH, et al. Selegiline in adults with attention deficit hyperactivity disorder: clinical efficacy and safety. Psychopharmacol Bull. 1996;32:327–334.
  • Fridman M, Hodgkins PS, Kahle JS, et al. Predicted effect size of lisdexamfetamine treatment of attention deficit/hyperactivity disorder (ADHD) in European adults: estimates based on indirect analysis using a systematic review and meta-regression analysis. Eur Psychiatry. 2015;30:521–527.

• Meta-analysis of efficacy of lisdexamfetamine both in adults and in children/adolescents.

  • Franke AG, Bagusat C, Rust S, et al. Substances used and prevalence rates of pharmacological cognitive enhancement among healthy subjects. Eur Arch Psychiatry Clin Neurosci. 2014;264:S83–S90.
  • Kessler RC, Green JG, Adler LA, et al. Structure and diagnosis of adult attention-deficit/hyperactivity disorder: analysis of expanded symptom criteria from the adult ADHD clinical diagnostic scale. Arch Gen Psychiatry. 2010;67:1168–1178.
  • Almeida LG, Ricardo-Garcell J, Prado H, et al. Reduced right frontal cortical thickness in children, adolescents and adults with ADHD and its correlation to clinical variables: a cross-sectional study. J Psychiatr Res. 2010;44:1214–1223.

•• Brain changes associated with ADHD.

  • Williamson D, Johnston C. Gender differences in adults with attention-deficit/hyperactivity disorder: a narrative review. Clin Psychol Rev. 2015;40:15–27.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.